Avelumab, a checkpoint antibody that is the mainstay of Merck KGaA’s immuno-oncology portfolio, has failed to show superior overall survival in patients with metastatic gastric cancer compared with chemotherapy. The data is from a Phase 3 trial called Javelin Gastric 300.
